In 2006, the first of two vaccines for human papillomavirus (HPV) prevention was approved for use in several countries. This has prompted great attention to be paid to HPV infections and their consequences. As the genital HPV types are acquired sexually, acceptability to the public of a vaccine to prevent a sexually transmitted infection (STI) will be an important issue in ensuring good uptake of the vaccine by those who would most benefit.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Block SL, Nolan T, Sattler C, Barr E, Giacoletti KED, and Marchant CD, et al. (2006). Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics, 118:2135–2145.
Bosch FX and de Sanjosé. (2003). Chapter 1: human papillomavirus and cervical cancer–burden and assessment of causality. J Natl Cancer Inst Monographs, 31:3–13.
Clifford G, Franceschi S, Diaz M, Munoz N, and Villa LL. (2006). Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine, 24(S3):26–34.
Cogliano V, Grosse y, Baan R, Straif K, Secretan B, and El Ghissassi F. (2005). Carcinogenicity of combined oestrogen–progestagen contraceptives and menopausal treatment. Lancet Oncol, 6:552–553.
Davis K, Dickman ED, Ferris D, and Dias JK. (2004) Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis, 8:188–194.
Dobson S, Deeks S, and Money D. (2007). National advisory committee on immunization (NACI) statement on human papillomavirus vaccine. Can Commun Dis Rep, 33:1–32.
Dubin G for the HPV Vaccine Adolescent Study Investigators, GlaxoSmithKline Biologicals, Rixensart, Belgium. (2005) Enhanced immunogenicity of a candidate human papillomavirus (HPV) 16/18 L1 virus-like particle vaccine (VLP) with novel ASO4 adjuvant in pre-teens/adolescents. Abstract No: 4042. Poster presented at ICAAC 2005.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, and Schuind A et al. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet, 364:1757–1765.
Harper DM, Franco EL, Wheeler C, Moscicki A, Romanowski B, and Roteli-Martins CM et al. (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet, 367:1247–1255.
Herrero R, Hildesheim A, Bratti C et al. (2000). Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst, 92:464–474.
Kahn JA, Zimet GD, Bernstein DI, Riedesel JM, Lan D, Huang B, and Rosenthal S. (2005). Pediatricians’ intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health, 37:502–510.
Kitchener HC, Castle PE, and Cox JT. (2006). Chapter 7: achievements and limitations of cervical cytology screening. Vaccine, 24(S3):63–70.
Lacey CJN, Lowndes CM, and Shah KV. (2006). Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine, 24(S3):35–41.
Moscicki AB, Schiffman M, Kjaer S, and Villa LL. (2006). Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine, 24(S3):42–51.
Munoz N, Castellsague X, Berrington de Gonzalez A, and Gissmann L. (2006). Chapter 1: HPV in the etiology of human cancer. Vaccine, 24(S3):1–10.
Riedesel JM, Rosenthal SL, Zimet GD, Bernstein DI, Huang B, Lan D, And Kahn JA. (2005). Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol, 18:391–398.
Sellors JW, Mahony JB, and Kaczorowski J, et al. (2000). Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ, 163:503–508.
Sellors JW, Karwalajtys TL, Kaczorowski J, Mahoney JB, Lytwyn A, Chong S, Sparrow J, Lorincz A. (2002). Prevalance of carcinogenic human papillomavirus (HPV) infection in older women. CMAJ, 167:871–873.
Shykhon M, Kuo M, and Pearman K. (2002). Recurrent respiratory papillomatosis. Clin Otolaryngol, 27:237–243.
Stanley M. (2006). Immune responses to human papillomavirus. Vaccine, 24(S1):16–22.
Stanley M, Lowy DR, and Frazer I. (2006). Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine, 24S3:106–113.
Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, and Giuliano AR, et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6:271–278.
Villa LL, Ault KA, Giuliano AR, Costa RLR, Petta CA, and Andrade RP, et al. (2006a). Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 24(27–28):5571–5583.
Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, and Iversen OE, et al. (2006b). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer, 95:1459–1466.
Winer RL, Lee SK, and Hughes JP et al. (2003). Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol, 157: 218–226.
World Health Organization. (2005). Preventing Chronic Diseases: A Vital Investment. WHO Global Report, Geneva.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer
About this paper
Cite this paper
Paulus, S., Dobson, S. (2008). Human Papillomavirus Vaccines: Who Should Get Them and Why?. In: Finn, A., Pollard, A.J. (eds) Hot Topics in Infection and Immunity in Children IV. Advances in Experimental Medicine and Biology, vol 609. Springer, New York, NY. https://doi.org/10.1007/978-0-387-73960-1_11
Download citation
DOI: https://doi.org/10.1007/978-0-387-73960-1_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-73959-5
Online ISBN: 978-0-387-73960-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)